SecurityKMR / Kinder Morgan, Inc. (49455U100)
IndustryNatural Gas Transmission
Common Shares Outstanding2,206,071,454 shares (as of 2018-03-31)
Total Insiders23
Total Directors11
Total Officers15

Stock Insider Trading (from SEC Form 4)

Kinder Morgan, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

KMR / Kinder Morgan, Inc. insiders include Sanders Dax, MORGAN MICHAEL C, Shorb Lisa M, Mathews Denise R Holland James E, and DeVeau David R, KUEHN RONALD L JR, Moffatt James Curtis, SAROFIM FAYEZ, STAFF JOEL V, MACDONALD DEBORAH, Schlosser John W, MARTIN THOMAS A, SHAPER C PARK, ANDERSON IAN D, Michels David Patrick, SMITH WILLIAM A, KEAN STEVEN J, Arenivas Jesse, Dang Kimberly A, McClain Ronald G., KINDER RICHARD D, GARDNER TED A, .

Insider Roster

Insider Dir Off 10% Shares Owned
Michels David Patrick VP and Chief Financial Officer
X 41,504
Mathews Denise R VP, Human Resources/Admin/IT
X 16,837
Arenivas Jesse VP (President, CO2)
X 14,060
SMITH WILLIAM A Director
X 28,612
STAFF JOEL V Director
X 73,765
Moffatt James Curtis VP and General Counsel
X
MACDONALD DEBORAH Director
X 17,386
SAROFIM FAYEZ Director
X 38,397,902
MARTIN THOMAS A V.P. (Pres.,Nat.Gas Pipelines)
X 1,147,019
Holland James E VP,(Pres.,Products Pipelines)
X 397,036
Shorb Lisa M V.P./Human Resources/Admin/IT
X
Sanders Dax V.P., Corporate Developement
X
Dang Kimberly A V.P. & Chief Financial Officer, Director
X X
KINDER RICHARD D Executive Chairman, Director, 10% Owner
X X X 245,846,090
MORGAN MICHAEL C Director
X
KUEHN RONALD L JR Director
X
DeVeau David R V.P. & General Counsel
X
Schlosser John W V.P. (President, Terminals)
X
ANDERSON IAN D VP (Pres,Kinder Morgan Canada)
X
GARDNER TED A Director
X
McClain Ronald G. V.P. (Pres.Products Pipelines)
X
KEAN STEVEN J President and CEO, Director
X X
SHAPER C PARK Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-01-22 4 SMITH WILLIAM A By Spouse P I 19.5169 5,500 28,612 558,418
2018-01-20 4 Arenivas Jesse F D 19.01 -3,152 14,060
2018-01-16 4 SAROFIM FAYEZ A D 19.39 10,320 38,397,902
2018-01-16 4 MACDONALD DEBORAH A D 19.39 5,160 17,386
2018-01-16 4 STAFF JOEL V A D 19.39 10,320 73,765
2017-12-05 4 MARTIN THOMAS A P D 17.095 3,000 1,147,019 19,608,290
2017-07-31 4 SMITH WILLIAM A By Spouse P I 20.2363 4,903 23,112 467,701
2017-07-17 4 Arenivas Jesse F D 19.54 -946 17,121
2017-05-31 4 Sanders Dax By Spouse P I 18.706 500 2,000 37,412
2017-05-31 4 Sanders Dax P D 18.708 500 273,927 5,124,626
2017-05-30 4 Sanders Dax By Mother's IRA P I 18.54 800 800 14,832
2017-05-30 4 Sanders Dax Joint Tenant P I 18.54 800 800 14,832
2017-05-30 4 KINDER RICHARD D P D 18.5785 500,000 245,846,090 4,567,451,583
2017-01-17 4 STAFF JOEL V A D 22.55 8,870 63,445
2017-01-17 4 SAROFIM FAYEZ A D 22.55 8,870 38,387,582
2016-12-15 4 MORGAN MICHAEL C By trust G I -7,535 4,384,518
2016-10-24 4 SAROFIM FAYEZ P D 21.4141 700,000 38,378,712 821,845,577
2016-07-16 4 Shorb Lisa M F D 21.03 -1,377 248,671
2016-07-16 4 Arenivas Jesse F D 21.03 -758 18,045
2016-02-01 4 Sanders Dax By Spouse P I 15.32 1,500 1,500 22,980
2016-02-01 4 Sanders Dax P D 15.32 1,500 273,427 4,188,902
2016-01-25 4 MORGAN MICHAEL C By Portcullis Partners, LP P I 14.1978 180,000 4,392,053 62,357,490
2016-01-19 4 SAROFIM FAYEZ A D 12.55 15,940 37,678,712
2016-01-19 4 STAFF JOEL V A D 12.55 15,940 54,575
2015-12-10 4 Sanders Dax P D 16.927 2,000 271,927 4,602,908
2015-11-13 4 McClain Ronald G. P D 22.8176 2,500 307,520 7,016,868
2015-11-11 4 MORGAN MICHAEL C By Portcullis Partners, LP P I 24.4 100,000 4,192,683 102,301,465
2015-11-09 4 MORGAN MICHAEL C By Portcullis Partners, LP P I 25.56 20,000 4,092,683 104,608,977
2015-11-09 4 MORGAN MICHAEL C By Portcullis Investments, LP P I 25.56 6,300 592,053 15,132,875
2015-11-11 4 MARTIN THOMAS A P D 24.48 10,000 1,144,019 28,005,585
2015-11-11 4 KINDER RICHARD D P D 24.69 100,000 245,346,090 6,057,594,962
2015-11-02 4 Dang Kimberly A P D 26.5 2,000 2,340,985 62,036,102
2015-10-30 4 Sanders Dax P D 27.4 1,000 269,927 7,396,000
2015-10-30 4 DeVeau David R P D 27.3994 11,000 354,132 9,703,004
2015-10-30 4 MARTIN THOMAS A P D 27.2414 10,000 1,134,019 30,892,265
2015-10-30 4 KEAN STEVEN J P D 27.428 18,150 7,544,774 206,938,061
2015-08-21 4 KEAN STEVEN J P D 32.166 7,500 7,526,624 242,101,388
2015-07-23 4 Schlosser John W S D 35.0646 -17,566 255,094 8,944,769
2015-07-24 4 KINDER RICHARD D P D 34.9744 100,000 245,246,090 8,577,334,850
2015-07-23 4 SAROFIM FAYEZ P D 35.0453 200,000 37,556,429 1,316,176,321
2015-07-22 4 SAROFIM FAYEZ By Spouse P I 35.5159 100,000 9,229,982 327,811,118
2015-07-22 4 SAROFIM FAYEZ P D 35.5159 200,000 37,356,429 1,326,747,197
2015-07-17 4 Arenivas Jesse F D 36.89 -235 18,803
2015-06-15 4 KEAN STEVEN J P D 39.383 6,000 7,519,124 296,125,660
2015-06-15 4 KEAN STEVEN J P D 39.373 6,000 7,513,124 295,814,231
2015-06-12 4 KINDER RICHARD D P D 38.9989 100,000 245,146,090 9,560,427,849
2015-06-05 4 KINDER RICHARD D P D 39.99 100,000 245,046,090 9,799,393,139
2015-04-23 4 Schlosser John W S D 44.48 -17,566 272,660 12,127,917
2015-04-21 4 SHAPER C PARK By Limited Liability Company S I 43.7386 -500,000 9,561,157 418,191,622
2015-04-20 4 SHAPER C PARK By Limited Liability Company S I 43.6528 -500,000 10,061,157 439,197,674
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

U.S. oil pipeline companies, producers seek relief from steel tariffs

1h reuters
HOUSTON (Reuters) - Major U.S. energy companies including Plains All American Pipeline (PAA.N), Hess Corp (HES.N) and Kinder Morgan Inc (KMI.N) are among many seeking exemptions from steel-import tariffs as the United States ratchets up trade tensions with exporters including China, Canada and Mexico. (9-0)

First of 202 Trans Mountain pipeline protesters await sentencing

10h cbc.ca
A couple of dozen anti-pipeline protesters rallied outside B.C. Supreme Court in Vancouver on Monday morning. (6-0)

Top Analyst Upgrades and Downgrades: BlackRock, Chevron, Disney, Intel, Kinder Morgan, Zillow and More

17h 247wallst
The futures traded lower again Monday morning as we look to see some follow-through selling in the wake of the announcement on the tariffs starting on some overseas products in early July. Investors should be heartened by the outstanding economic news that continues to pour in, and with only two weeks left in the second quarter, it’s a solid bet that earnings will be very positive. (115-2)

John Horgan wants your dad jokes — but also your personal information

21h cbc.ca
These are obviously bad jokes. But they're also bad jokes told by John Horgan, premier of British Columbia, in scripted videos released to the public. (6-0)

John Horgan wants your dad jokes — but also your personal information

2018-06-17 cbc.ca
These are obviously bad jokes. But they're also bad jokes told by John Horgan, premier of British Columbia, in scripted videos released to the public. (6-0)